Inhibition of CXCR2 suppresses myeloid‐derived suppressor cell recruitment and enhances anti‐PD‐1 therapeutic efficacy in rhabdomyosarcoma.[58] Additionally, previous studies have demonstrated that CXCL5 recruits neutrophils and other immune cells to the TME.[59, 60] However, the effect of CXCL5, either independently or in combination with other cytokines, on polarization toward the M2 phenotype remains unexplored. The gene discussed is CXCL5; the disease is rhabdomyosarcoma.